文摘
Chronic hepatitis C (CHC) and iron overload are the main causes of liver disease in β-thalassemia major (βTM). There is limited data regarding the course of CHC in this population. All patients (n--44) from the thalassemia centre of the University Hospital of Patras were evaluated (January 1981 to June 2012). Patients were classified into group A (n--7), which consisted of patients with CHC, who either had received antiviral treatment (n--9) or not (n--), and group B which included 87 patients without CHC. Nineteen patients died during follow-up (median: 257.5?months (1-55)). Survival rates were 84.2?% and 88.5?% for group A and B, respectively. The causes of death were heart failure (63.2?%), accident (10.5?%), sepsis (5.3?%), liver failure (5.3?%), hepatocellular carcinoma (HCC) (5.3?%), non-Hodgkin lymphoma (5.3?%) and multiorgan failure (5.3?%). There were no differences in total survival between the two groups (p--.524). In the multivariate analysis, survival was neither correlated with CHC (p-?ns), nor with anti-HCV treatment (p-?ns), whereas independent negative predictors were presence of heart failure (p-lt;-.001), presence of malignancy other than HCC (p--.001) and non-adherence to chelation treatment (p--.013). Predictive factors for the development of cirrhosis were: CHC (p-lt;-.001), age-gt;-5?years (p--.007), siderosis grade 3/4 (p--.029) and splenectomy (p--.001); however, multivariately, only siderosis grade 3/4 was found to be significant (p--.049). In this study, survival of patients with βTM was mainly associated with heart failure, presence of malignancy other than HCC and non-adherence to chelation treatment, rather than with liver disease. Multicentre studies need to be designed to define more accurately the indications of antiviral treatment in this population.